Amgen (NASDAQ:AMGN) today released its 2021 Environmental, Social & Governance (ESG) report, providing a comprehensive overview of the many ways the Company is doing its part to build a better, healthier world.
“Our core business of improving human health, in and of itself, contributes meaningfully to the greater good,” said Judy Brown, senior vice president, Corporate Affairs at Amgen, “and through our ESG programs, we are building on that foundation to address other challenging issues facing our society.”
Amgen’s latest ESG report tracks the Company’s progress across four categories:
- Healthy People: We focus on removing barriers that limit equitable access to healthcare so that people can live their healthiest lives. In 2021, for example, the Amgen Safety Net Foundation1 provided $2.2 billion2 of the Company’s medicines, at no cost, to uninsured or underinsured patients in the U.S.
- Healthy Society: We work toward a more just society for our employees and the people we serve. In 2021, no-cost science education programs funded by the Amgen Foundation1 reached more than 27 million students and educators globally, inspiring the next generation of innovators and helping to level the playing field for those who traditionally have lacked access to world-class science education.
- Healthy Planet: We prioritize sustainability and aim to minimize our environmental impact to preserve natural resources for generations to come. Amgen made continued progress last year toward its goal of achieving carbon neutrality in our operations by 20273.
- A Healthy Amgen: We hold ourselves to high standards in our operations – working to ensure our actions and culture reflect Amgen values. In 2021, Amgen added an ESG goal to the Company’s goals for our annual incentive plans to focus our entire Company on activities supporting achievement of our 2027 environmental sustainability targets and to strengthen and improve the Company’s diversity, inclusion, and belonging efforts. To further our progress, Amgen has included an ESG goal again for 2022.
Amgen’s ESG progress is reflected in the wide range of recognitions the Company has earned. In just the past six months, Amgen has been named to Newsweek magazine’s list of “America’s Most Responsible Companies” for the third consecutive year; JUST Capital’s list of “America’s Most JUST Companies” for the fifth consecutive year; Barron’s list of “America’s Most Sustainable Companies” for the second consecutive year; and the Human Rights Campaign Foundation’s list of “Best Places to Work for LGBTQ+ Equality” for the sixth consecutive year.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 World’s Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron’s.